A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340

NCT01601834 | Completed Phase 1

• 1 other identifier: B5261001
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study in healthy people is to evaluate safety, toleration and time course of plasma concentration of single oral doses of PF-06273340. The effect of food on the Pharmacokinetic of PF-06273340 may also be investigated.

Conditions

PAIN

Keywords

Phase 1; Single Dose; Pharmacokinetics; Safety; Toleration

Outcome Measures

Primary Outcomes (9)

• Maximum observed plasma concentration (Cmax)

  0,0.25,0.5,1,1.5,2,4,6,8,12,24,36,48,72 hours post-dose

• Time of maximum concentration (Tmax)

  0,0.25,0.5,1,1.5,2,4,6,8,12,24,36,48,72 hours post-dose

• Area under the plasma concentration time profile from time zero to the time of last quantifiable concentration (AUClast)

  0,0.25,0.5,1,1.5,2,4,6,8,12,24,36,48,72 hours post-dose

• Area under the plasma concentration time profile from time zero extrapolated to inifinite time (AUCinf)

  0,0.25,0.5,1,1.5,2,4,6,8,12,24,36,48,72 hours post-dose

• Area under the plasma concentration time profile from time zero to quantifiable concentration 24 h post dose (AUC24)

  0,0.25,0.5,1,1.5,2,4,6,8,12,24,36,48,72 hours post-dose

• Apparent Clearance (CL/F)

  0,0.25,0.5,1,1.5,2,4,6,8,12,24,36,48,72 hours post-dose

• Apparent Volume of Distribution (Vz/F)

  0,0.25,0.5,1,1.5,2,4,6,8,12,24,36,48,72 hours post-dose

• t1/2 = Terminal Elimination half life

  0,0.25,0.5,1,1.5,2,4,6,8,12,24,36,48,72 hours post-dose

• Urine: Ae24 (amount excreted in urine), Ae24% (%dose excreted in urine to time 24 h) and CLr (Renal Clearance) for selected doses

  up to 24 h

Study Arms (2)

Cohort 1: Experimental intervention: PF-06273340 or placebo

EXPERIMENTAL

Subjects in Cohort 1 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.

Drug: PF-06273340 or Placebo

Cohort 2: Experimental intervention: PF-06273340 or placebo

EXPERIMENTAL

Subjects in Cohort 2 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.

Drug: PF-06273340 or Placebo

Interventions

PF-06273340 or Placebo DRUG

PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.

Cohort 1: Experimental intervention: PF-06273340 or placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male subjects or female subjects of non-child bearing potential between the ages of 18 and 55 years, inclusive.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).
• An informed consent document signed and dated by the subject
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

You may not qualify if:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Any condition possibly affecting drug absorption (e.g., gastrectomy).
• A positive urine drug screen.
• History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
• Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
• Screening supine blood pressure \>= 140 mm Hg (systolic) or \>= 90 mm Hg (diastolic), on a single measurement (confirmed by a single repeat, if necessary) following at least 5 minutes of rest.
• lead ECG demonstrating QTc \>450 msec at screening. If QTc exceeds 450 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
• Females of child bearing potential.
• Use of prescription or non-prescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
• Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing. History of sensitivity to heparin or heparin-induced thrombocytopenia.
• Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (1)

Pfizer Investigational Site

Brussels, B-1070, Belgium

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Pain

Interventions

PF-06273340

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2012
• First Posted: May 18, 2012
• Study Start: May 1, 2012
• Primary Completion: June 1, 2012
• Study Completion: June 1, 2012
• Last Updated: July 4, 2012

Record last verified: 2012-07

Locations

BE (1)